A Prospective Study of Pediatric Participants up to 16 Years of Age With Methylmalonic Acidemia (MMA) Due to Mutations in the MMUT Gene

NCT07432880 | Recruiting

• 1 other identifier: MMA-OBS-01
• Study Type: observational
• Target: 30
• Locations: 4 countries
• Sites: 8

Brief Summary

Methylmalonic Acidemia (MMA) is a severe and rare condition that affects how the body turns food into energy. In people with MMA, the body is missing or has a very low activity of a specific protein (an enzyme called methylmalonyl-CoA mutase (MMUT)) needed to break down certain proteins and fats in everyday food. Because this process does not work properly, a harmful substance called methylmalonic acid builds up in the blood and tissues, causing damage in the body. Most people with MMA have an altered MMUT gene, which affects the enzyme methylmalonyl-CoA mutase. MMA often appears in infancy or early childhood, but some people are diagnosed later. MMA affects approximately 1 in every 100,000 babies born and primarily impacts the liver, brain and kidneys. MMA poses significant challenges as it can result in complications such as dangerous acid levels in the blood, problems with the brain and nerves, visions problems, problems with how the pancreas, liver, and the kidneys work, as well as growth and development delays. The main purpose of this observational study that tracks how the disease develops over time is to gather necessary data and evidence to confirm which signs in the body and blood test results can reliably show disease activity related to MMA. These confirmed signs and blood test results will be used for future research into developing new treatments for MMA. The data will be collected from participants with severe symptoms with and without liver transplant.

Conditions

Methylmalonic Acidemia (MMA)

Keywords

MMA, MCA, observational, MUT, MMUT,

Outcome Measures

Primary Outcomes (1)

• Evaluation of disease progression using biochemical biomarkers

  Change over time in biomarkers to evaluate disease progression and/or organ transplantation.

  Baseline, Month 6, Month 12, Month 18, Month 24, Month 30 and Month 36

Secondary Outcomes (2)

• Evaluate metabolic stability

  Baseline, Month 6, Month 12, Month 18, Month 24, Month 30 and Month 36

• Evaluate disease trajectory outcomes

  Baseline, Month 6, Month 12, Month 18, Month 24, Month 30 and Month 36

Study Arms (2)

Unstransplanted severe MMA

without previous liver (or combined liver/kidney) transplantation at time of screening

Transplanted severe MMA

with previous liver (or combined liver/kidney) transplantation at time of screening

Eligibility Criteria

• Age: Up to 16 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

The participants will come from the participating hospital where they are routinely follow up for their disease and their routine care

You may qualify if:

• Aged ≤16 years at screening visit
• With or without previous liver (or combined liver/kidney) transplantation at time of screening (note: number of transplanted participants capped at n=15) 3. Confirmed laboratory diagnosis of Isolated MMA caused by mutations in the MMUT gene (NOTE: if a historical genetic mutational analysis report was available at Screening visit but was not from a CLIA/ISO15189 approved laboratory, a confirmatory sample will be taken during the study. However the original lab report will be adequate for study eligibility consideration)..
• \. Severe MMA phenotype.
• For untransplanted participants, all of the following criteria (a-c) must be met to qualify as "severe" MMA phenotype:
• Serum methylmalonic acid (sMMA) level of \>100 µmol/L at the Screening visit
• An unscheduled ER visit, hospitalization or requirement for use of the sick day diet regimen in the 12 months prior to the screening visit
• Considered to potentially require future liver transplantation to improve metabolic stability in accordance with MMA transplantation guidelines (Baumgartner 2014, Forny 2021, Sen 2023)
• For participants with previous liver or combined liver and kidney transplantation, the phenotype of the participant will be judged by the Investigator to be severe if both of the following were applicable prior to transplantation:
• Pre-transplant serum methylmalonic acid (sMMA) level of \>100 µmol/L AND
• Transplantation was conducted to improve metabolic stability in accordance with MMA transplantation guidelines (Baumgartner 2014, Forny 2021, Sen 2023).
• NOTE: sMMA pre-transplant measure must have been obtained within 6 months prior to transplant. An alternative blood MMA concentration may be used (e.g. plasma MMA, or dry blood spot), if sMMA is unavailable. Details of the assay used must be provided and additional samples will be collected during the study to allow comparison to sMMA results.

You may not qualify if:

• Participant/parent/legal guardian/caregiver not willing to consent to participate
• Current participation in another interventional or therapeutic study
• Prior participation in a gene therapy clinical trial including mRNA therapy
• Participants who, in the opinion of the Site Investigator, would be unable or unsuitable to participate in the demands of the study, for example but not limited to participants unable to travel to protocol study visits or participants under palliative care.
• For participants who are post-liver transplant only, participant will be excluded if no prior pre-liver transplant measurements of blood MMA are available.

Sponsors & Collaborators

• Genespire Srl: lead

Study Sites (8)

CHOP (Children's hospital of Philadelphia)

Philadelphia, Pennsylvania, 19104, United States

NOT YET RECRUITING

UPMC (Children's hospital of Pittsburgh)

Pittsburgh, Pennsylvania, 15224, United States

NOT YET RECRUITING

OSR_San Raffaele

Milan, 20132, Italy

NOT YET RECRUITING

OBGP (Bambino Gesu Ospedale Pediatrico)

Roma, 00146, Italy

NOT YET RECRUITING

SJD_San Joan de Deù Children's Hospital

Barcelona, 08950, Spain

NOT YET RECRUITING

Hospital Universitario 12 de Octubre

Madrid, 28041, Spain

NOT YET RECRUITING

GOSH NHS (Great Ormond Street Hospital for Children)

London, WC1N 3JH, United Kingdom

RECRUITING

Saint Mary's Hospital

Manchester, M13 9WL, United Kingdom

NOT YET RECRUITING

MeSH Terms

Conditions

Methylmalonic acidemia

Study Officials

• simon Hawkins

  Genespire Srl

  STUDY DIRECTOR

Central Study Contacts

Gwenaelle roguet, MD

CONTACT

+33 0745017668; clinical.operations@genespire.com

simon Hawkins, PhD

CONTACT

simon.hawkins@genespire.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 28, 2026
• First Posted: February 25, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): May 1, 2030
• Study Completion (Estimated): May 1, 2030
• Last Updated: July 23, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: CSR
• Time Frame: May 2031

Locations

GB (2); ES (2); US (2); IT (2)